Screening Test Shows Prognostic Value for NSCLC

Share this content:

(ChemotherapyAdvisor) – VeriStrat may be useful for clinical decision-making in patients with non-small cell lung cancer (NSCLC), according to a study presented by a multinational team of researchers at the third annual European Lung Cancer Conference in Geneva, Switzerland. The study, entitled “Serum Proteomic Classifier for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Erlotinib and Bevacizumab in First Line: Pooled Analysis of Phase 2 Trials SAKK19/05 AND NTR528,” is listed as Abstract# 80O_PR.

VeriStrat is a proteomic-based serum test that reports two labels: VeriStrat Good (VSG) or VeriStrat Poor (VSP); according to published studies, VSG patients perform better than VSP patients upon treatment with EGFR TKIs. The authors aimed to explore VeriStrat's ability to separate patients with advanced non-squamous NSCLC treated with bevacizumab and erlotinib (BE) into groups based on their progression-free survival (PFS) and overall survival (OS). Data were obtained from 117 patients previously enrolled in 2 European Phase 2 trials of first-line BE (NCT00354549 and NTR528) and analyzed using VeriStrat.

The authors reported that VeriStrat analysis classified 87 (74%) as VSG, 27 (23%) as VSP, and 3 (3%) as indeterminate. “VSG and VSP demonstrated a statistically significant difference in OS (P=0.0027, HR=0.480, 95% confidence interval (CI): 0.294–0.784) but significance for PFS was not reached (P=0.2632, HR=0.768, 95% CI: 0.482–1.223).”

The authors concluded: “These results support the notion that VeriStrat may be useful for clinical decision-making, representing a prognostic and potentially a predictive biomarker for treatment with EGFR TKIs. This predictive value of VeriStrat will be tested in a prospective clinical trial in advanced squamous cell lung carcinoma, sponsored by the European Thoracic Oncology Platform (ETOP).”

Abstract 80O_PR

Press Release

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs